aTyr Pharma Doses First Subjects in Phase 1 Trial of iMod.Fc (ATYR1923)
November 27, 2017 08:00 ET
|
aTyr Pharma, Inc.
– Second Physiocrine-based therapeutic candidate enters the clinic – – Top-line data expected in 2Q 2018 – – iMod.Fc (ATYR1923) to target interstitial lung diseases with an immune component – SAN...
aTyr Pharma Announces Third Quarter 2017 Operating Results and Provides Corporate Update
November 14, 2017 16:05 ET
|
aTyr Pharma, Inc.
- Initiation of Phase 1 clinical trial of iMod.Fc on-track for this quarter - - Selection of antibody for ORCA program on-track for this quarter - SAN DIEGO, Nov. 14, 2017 (GLOBE NEWSWIRE) -- aTyr...
aTyr Pharma Announces Leadership Transition
November 01, 2017 16:05 ET
|
aTyr Pharma, Inc.
– Dr. John Mendlein Transitions from CEO to Non-Executive Board Member,Dr. Sanjay Shukla Appointed President and CEO – SAN DIEGO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE),...
aTyr Pharma to Present at Two Upcoming Investor Conferences in September
September 05, 2017 23:00 ET
|
aTyr Pharma Inc.
SAN DIEGO, Sept. 05, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of immunology-based therapeutics, harnessing new...
aTyr Pharma to Present at Jefferies 2017 Global Healthcare Conference
May 31, 2017 09:00 ET
|
aTyr Pharma Inc.
SAN DIEGO, May 31, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe,...
aTyr Pharma Announces Presentations on Interstitial Lung Disease and the iMod.Fc Program at the American Thoracic Society 2017 International Conference and Will Host an Educational Webinar
May 15, 2017 08:00 ET
|
aTyr Pharma Inc.
- Poster Presentations to Explore Potential of Augmenting Resokine Pathway in Severe, Rare Pulmonary Diseases with an Immune or Fibrotic Component - - Conference Call and Webcast Featuring Guest...
aTyr Pharma Announces First Quarter 2017 Operating Results
May 11, 2017 16:05 ET
|
aTyr Pharma Inc.
– Announced Promising Top-Line Results from ResolarisTM Phase 1b/2 Trial in Early Onset FSHD –– Preclinical Data from StalarisTM Program to be Presented at American Thoracic Society...
aTyr Pharma Announces Appointment of Timothy P. Coughlin to its Board of Directors
April 10, 2017 17:00 ET
|
aTyr Pharma Inc.
SAN DIEGO, April 10, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe,...
aTyr Pharma to Present at Needham and Company 16th Annual Healthcare Conference
March 29, 2017 09:00 ET
|
aTyr Pharma Inc.
SAN DIEGO, March 29, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe,...